Olivier Trédan - Concepedia

Author

Olivier Trédan

Also Known As

László Landherr, M. Timar-David, O Tredan, O Trédan, O. Tredan, O. Trédan, OLIVIER TREDAN, Olivier TREDAN, Olivier Trdan, Olivier Tredan

552

Publications

17K

Citations

H-Index

102

Concepts

All Affiliations

Centre Léon Bérard Inserm Université Claude Bernard Lyon 1 Centre National de la Recherche Scientifique Institut Curie

About

Olivier Trédan is an author at Centre Léon Bérard specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	55	7.6K
2	Health Sciences	12	12	482
3	Public Health	2	2	144
4	Engineering	1	1	156
5	Biostatistics	1	1	83

Olivier Trédan

136

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer Matthew P. Goetz, Masakazu Toi, Mario Campone, Journal of Clinical Oncology Breast OncologyEndocrine-related CancerMedicinePharmacologyPurpose Abemaciclib	2017	1.7K
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès, The Lancet Oncology Advanced CancerDrug TargetingOncologyMedicineVersus Conventional Therapy	2015	1.1K
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, Cancer Research	2009	780
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hope S. Rugo, Aditya Bardia, Frederik Marmé, The Lancet	2023	363
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) Hervé Bonnefoi, Thomas Grellety, Olivier Trédan, Annals of Oncology Metastatic Breast CancerOncologyBreast OncologyMedicineAbiraterone Acetate	2016	275
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hope S. Rugo, Aditya Bardia, Frederik Marmé, Journal of Clinical Oncology	2022	275
Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer Sana Intidhar Labidi‐Galy, Vanja Sisirak, Pierre Méeus, Cancer Research Immune ToleranceFunctional AlterationsImmunologyImmune RegulationImmunoediting	2011	231
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel P. Sève, John R. Mackey, Sylvie Isaac, Molecular Cancer Therapeutics	2005	218

Page 1